Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Glaxosmithkline Llc patents


Recent patent applications related to Glaxosmithkline Llc. Glaxosmithkline Llc is listed as an Agent/Assignee. Note: Glaxosmithkline Llc may have other listings under different names/spellings. We're not affiliated with Glaxosmithkline Llc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxosmithkline Llc-related inventors


Phospholipidation of imidazoquinolines and oxoadenines

. . . . The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. ... Glaxosmithkline Llc

Dosing regimen of combination of anti-cd20 and anti-blys antibodies

The present invention relates to a cd20 binding antibody which is capable of depleting b cells, and a blys binding antibody which is capable of antagonizing blys, as a combination for use in the treatment of an autoimmune disorder. The invention also relates to dosages, duration of treatment and time lapses between administration of the cd20 binding antibody which is capable of depleting b cells, and the blys binding antibody which is capable of antagonizing blys.. ... Glaxosmithkline Llc

Cytomegalovirus antigens

The invention generally relates to recombinant human cytomegalovirus (cmv) gb proteins and immunogenic fragments thereof, which do not comprise a transmembrane (tm) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gb, and/or adhesion of the monomeric trimer of gb to the host cell.. . ... Glaxosmithkline Llc

Benzimidazole derivatives as pi3 kinase inhibitors

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. ... Glaxosmithkline Llc

Biopharmaceutical compositions

The present disclosure relates to compositions, for treating interleukin 5 (il-5) mediated diseases, and related methods.. . ... Glaxosmithkline Llc

Novel methods for inducing an immune response

The present invention relates to methods for inducing an immune response, in particular methods for inducing an immune response against mycobacterial infections or disease comprising (i) at least one administration of a polypeptide rv1196 related antigen and at least one administration of an adenovirus encoding a rv1196 related antigen or (ii) at least one administration of a polypeptide rv0125 related antigen and at least one administration of an adenovirus encoding a rv0125 related antigen. Associated compositions, adenoviral constructs and polynucleotide sequences are also provided.. ... Glaxosmithkline Llc

Pre-fusion rsv f antigens

. . The invention relates to pre-fusion rsv f protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion rsv f.. ... Glaxosmithkline Llc

Combination therapy

The present invention provides methods for increasing expression of at least one co-stimulatory and/or co-inhibitory receptor on a t cell comprising contacting said t cell with an anti-ctla4 antibody. In one aspect the co-stimulatory and/or co-inhibitory receptor is selected from the group of: pd-1, ox40, icos, cd137, tim3, and lag3. ... Glaxosmithkline Llc

Gdnf induction for the treatment of retinal disorders

Methods and compositions for glial cell-derived neurotrophic factor (gdnf) induction in the eye, and for treatment and/or prevention of retinal disorders are described.. . ... Glaxosmithkline Llc

Combination treatments and uses and methods thereof

Disclosed herein are combinations of an ox40 modulator and a ctla-4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.. . ... Glaxosmithkline Llc

Combination treatments and uses and methods thereof

Disclosed herein are combinations of an ox40 modulator and a pd-1 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.. . ... Glaxosmithkline Llc

Antibody variants

The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.. ... Glaxosmithkline Llc

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same.. ... Glaxosmithkline Llc

Tlr4 agonists and compositions thereof and their use in the treatment of cancer

Disclosed is a tlr4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.. . ... Glaxosmithkline Llc

08/02/18 / #20180216081

Novel adenovirus

. . There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.. . ... Glaxosmithkline Llc

08/02/18 / #20180214531

Meningococcus vaccines

Meningococcal vaccines can be improved by including multiple alleles or variants of fhbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an omv component in each dose.. . ... Glaxosmithkline Llc

08/02/18 / #20180214379

Pharmaceutical composition comprising an adenoviral vector

The present invention relates to the formulation of adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration, its formulation as well as a method for obtaining the dried composition.. . ... Glaxosmithkline Llc

07/26/18 / #20180208955

Microbiological process

A process for the microbial synthesis of migalastat, specifically a process for the production of migalastat comprising culturing a microorganism under conditions such that at least one imino sugar is produced and detecting and/or isolating an imino sugar produced by said microorganism, and the microorganisms used in this process. The invention also comprises migalastat produced according to the above method and pharmaceutical compositions and uses thereof.. ... Glaxosmithkline Llc

07/26/18 / #20180207262

Pneumococcal capsular saccharide conjugate vaccine

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22f saccharide conjugate. ... Glaxosmithkline Llc

07/26/18 / #20180207145

Pharmaceutical compositions comprising danirixin for treating infectious diseases

Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.. . ... Glaxosmithkline Llc

07/26/18 / #20180207144

Enhancer of zeste homolog 2 inhibitors

This invention relates to novel substituted benzamide according to formula (i) which are inhibitors of enhancer of zeste homolog 2 (ezh2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.. . ... Glaxosmithkline Llc

07/12/18 / #20180194756

Novel soluble guanylate cyclase activators and their use

. . The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.. ... Glaxosmithkline Llc

07/05/18 / #20180186801

Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

. . Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. ... Glaxosmithkline Llc

06/28/18 / #20180177871

Adjuvanted formulations of booster vaccines

The invention improves tdap vaccines by including a tlr agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.. ... Glaxosmithkline Llc

06/21/18 / #20180170871

Crystalline forms

. . . . . . This invention relates to crystalline forms of (r)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.. . ... Glaxosmithkline Llc

06/21/18 / #20180169210

Hybrid and tandem expression of neisserial proteins

Two or more neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula nh2-a-[—x-l-]n—b—cooh where x is an amino acid sequence, l is an optional linker amino acid sequence, a is an optional n-terminal amino acid sequence, b is an optional c-terminal amino acid sequence, and n is an integer greater than 1. ... Glaxosmithkline Llc

06/21/18 / #20180169206

Immunogenic compositions

This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with shigella strains.. . ... Glaxosmithkline Llc

06/21/18 / #20180169204

Combination vaccines with lower doses of antigen and/or adjuvant

Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. ... Glaxosmithkline Llc

06/14/18 / #20180162845

Enhancer of zeste homolog 2 inhibitors

This invention relates to novel compounds according to formula (i) which are inhibitors of enhancer of zeste homolog 2 (ezh2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.. . ... Glaxosmithkline Llc

06/07/18 / #20180153983

Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides

. . The invention provides a process for preparing a conjugate of a s.aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. ... Glaxosmithkline Llc

05/31/18 / #20180147194

Novel compounds as rearranged during transfection (ret) inhibitors

This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. . ... Glaxosmithkline Llc

05/24/18 / #20180140084

Oral cleaning implement with a tool adapted for removal of denture adhesive from dentures

. . Aspects of the present invention are directed to an oral cleaning implements having a head and a handle. The implements distal end of the handle may be a tool adapted for removal of denture adhesive from dentures.. ... Glaxosmithkline Llc

05/17/18 / #20180134688

Novel compounds

. . The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of rip2 kinase, including degrading rip2 kinase, the treatment of diseases and conditions mediated by the rip2 kinase, in particular for the treatment of inflammatory diseases or conditions.. ... Glaxosmithkline Llc

05/10/18 / #20180125968

Poxviral vaccines

. . The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.. ... Glaxosmithkline Llc

05/03/18 / #20180118733

Lap e3 ligase directed proteolysis targeting chimeric molecules

. . The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of rip2 kinase, including degrading rip2 kinase, the treatment of diseases and conditions mediated by the rip2 kinase, in particular for the treatment of inflammatory diseases or conditions.. ... Glaxosmithkline Llc

05/03/18 / #20180117165

Covalent conjugates of bet inhibitors and alpha amino acid esters

The present invention relates to covalent conjugates of bet inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.. . ... Glaxosmithkline Llc

04/19/18 / #20180104323

Immunogenic composition

. . The present application relates to immunogenic compositions comprising type 5 and/or 8 capular polysaccharide or oligosaccharide from s. Aureus having between 30-100% o-acetylation. ... Glaxosmithkline Llc

04/19/18 / #20180104322

Immunogenic composition for use in therapy

This application relates to immunogenic compositions comprising a staphylococcus aureus type 5 capsular saccharide conjugated to a carrier protein to form a s. Aureus type 5 capsular saccharide conjugate.. ... Glaxosmithkline Llc

04/12/18 / #20180099979

Novel compounds as diacylglycerol acyltransferase inhibitors

. . This invention relates to methods for the preparation of a compound which is an inhibitor of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1).. . ... Glaxosmithkline Llc

04/12/18 / #20180099976

Novel compounds as rearranged during transfection (ret) inhibitors

This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. . ... Glaxosmithkline Llc

04/12/18 / #20180099955

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. . ... Glaxosmithkline Llc

04/12/18 / #20180099948

Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Disclosed are novel crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Llc

04/05/18 / #20180092970

Chlamydia antigens

The invention provides chlamydia antigens for use in the treatment, prevention and/or diagnosis of chlamydia infection. In particular, the invention provides antigens ct733, ct153, ct601, ct279, ct443, ct372, ct456, ct381, ct255, ct341, ct716, ct745, ct387, ct812, ct869, ct166, ct175, ct163, ct214, ct721, ct127, ct043, ct823 and/or ct600 from c. ... Glaxosmithkline Llc

03/29/18 / #20180085388

Delivery of rna to trigger multiple immune pathways

. . Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen. ... Glaxosmithkline Llc

03/22/18 / #20180079831

Novel process

The present invention relates to the use of extrusion technology in a process for the low-moisture continuous gelatinisation and the enzymatic hydrolysis of flour to provide a dextrinised product having a dextrose equivalent (de) of at least 15 and to a process for drying a dextrinised product.. . ... Glaxosmithkline Llc

03/22/18 / #20180079722

Hydrobromide salt of n-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea

A compound which is the hydrobromide salt of n-{4-chloro-2-hydroxy-3-[(3s)-3-piperidinylsulfonyl]phenyl}-n′-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.. ... Glaxosmithkline Llc

03/22/18 / #20180078351

Toothbrush

The present invention is concerned with a toothbrush, in particular an electric or otherwise driven toothbrush having a rotatable head, wherein the head incorporates arrays of bristle tufts, at least some of which extend substantially radially of the axis of rotation.. . ... Glaxosmithkline Llc

03/15/18 / #20180071378

Mycobacterium antigenic composition

Immunogenic compositions comprising an m72 related antigen, wherein the conductivity of the composition is 13 ms/cm or lower, or the concentration of salts of the composition is 130 mm or lower, and their use in medicine, are provided.. . ... Glaxosmithkline Llc

03/08/18 / #20180064806

Immunogenic composition

Present application discloses an immunogenic composition comprising n. Meningitidis capsular polysaccharides from at least one of serogroups a, c, w135 and y conjugated to a carrier protein to produce a n. ... Glaxosmithkline Llc

03/08/18 / #20180064801

Vaccines for neisseria gonorrhoeae

Methods and compositions for immunizing a human subject against neisseria gonorrhoeae.. . ... Glaxosmithkline Llc

03/08/18 / #20180064656

Topical pharmaceutical compositions

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.. ... Glaxosmithkline Llc

03/01/18 / #20180057582

Methods of treatment of eosinophilic bronchitis with an anti-il-5 antibody

The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by il-5 and excess eosinophil production, and more specifically to mabs, fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-il-5 antibody or fragment thereof.. ... Glaxosmithkline Llc

03/01/18 / #20180057540

Simian adenovirus nucleic acid-and amino acid-sequences, vectors containing same, and uses thereof

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. ... Glaxosmithkline Llc

02/22/18 / #20180051275

Method for purifying viral vectors

The invention relates to methods of purifying viral vectors from cell culture. In particular, the invention relates to a method of purifying a supernatant containing viral vectors from a cell culture, comprising removing cells by filtering said cell culture using diatomaceous earth.. ... Glaxosmithkline Llc

02/22/18 / #20180050059

Delivery of rna to different cell types

Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen. ... Glaxosmithkline Llc

02/15/18 / #20180044366

Novel crystalline forms of an antiviral benzimidazole compound

. . The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-l-ribofuranosyl-1hbenzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.. . ... Glaxosmithkline Llc

02/15/18 / #20180044338

Substituted bridged urea analogs as sirtuin modulators

Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. ... Glaxosmithkline Llc

02/15/18 / #20180043005

Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins

The present invention relates to immunogenic compositions comprising isolated clostridium difficile cdtb and/or cdta protein. In particular the isolated clostridium difficile cdtb protein is suitably a truncated cdtb protein comprising the receptor binding domain or a mutated cdtb protein incapable of binding to cdta, and the isolated clostridium difficile cdta protein is suitably a truncated cdta protein which does not comprise the c-terminal domain. ... Glaxosmithkline Llc

02/15/18 / #20180042944

Pharmaceutical compositions

The present invention relates to long acting pharmaceutical compositions of betulin derivatives or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of human immunodeficiency virus (hiv) infections.. . ... Glaxosmithkline Llc

02/08/18 / #20180036403

Compositions and uses

The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.. . ... Glaxosmithkline Llc

02/08/18 / #20180036402

Immunogenic compositions

A method of immunization against group b streptococcus infection, using an immunogenic composition conjugates of gbs capsular saccharide conjugated to carrier proteins.. . ... Glaxosmithkline Llc

02/01/18 / #20180028641

Multiple variants of meningococcal protein nmb1870

Meningococcal protein nmb 1870 has been described in the prior art. The inventors have found that nmb 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. ... Glaxosmithkline Llc

01/25/18 / #20180023122

Novel processes for the production of oligonucleotides

Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.. . ... Glaxosmithkline Llc

01/25/18 / #20180022799

Methods for administering anti-il-5 antibodies

The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by il-5 and excess eosinophil production, and more specifically to mabs, fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-il-5 antibody, wherein at least one anti-il-5 antibody provides a mean maximum plasma concentration of said anti-il-5 antibody of at least about 1.03±0.21 μg/ml, an area under the curve(0-inf) value of at least about 15.5±2.7 μg*day/ml and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days.. ... Glaxosmithkline Llc

01/25/18 / #20180022737

Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

Disclosed are novel crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Llc

01/25/18 / #20180021417

Adjuvant compositions comprising a non-ionic isotonicity agent

The present invention relates to an aqueous adjuvant composition comprising a tlr-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.. . ... Glaxosmithkline Llc

01/25/18 / #20180021409

Pharmaceutical composition

The present invention provides liquid compositions comprising albiglutide or a variant thereof, a buffering agent, at least one saccharide and/or at least one polyol, at least one stabilizing agent and optionally a surfactant wherein said albiglutide remains stable in said liquid composition. Albiglutide or a variant thereof can be considered to remain stable in liquid if at least about ≧96% of said albiglutide or a variant thereof remains as a monomer in the liquid composition over a period of at least one week.. ... Glaxosmithkline Llc

01/18/18 / #20180015159

Cmv antigens and uses thereof

The invention relates to a recombinant human cytomegalovirus (cmv) protein dimeric complex comprising cmv gh protein or a complex-forming fragment thereof, and cmv ul116 or a complex-forming fragment thereof. Also provided herein are nucleic acids encoding said gh/ul116 dimeric complex, host cells for recombinant expression of said gh/ul116 dimeric complex, and the use of said gh/ul116 dimeric complex for use as a vaccine antigen.. ... Glaxosmithkline Llc

01/11/18 / #20180009852

Immunogenic bacterial vesicles with outer membrane proteins

Knockout of the meningococcal mlta homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than omvs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mlta gene. ... Glaxosmithkline Llc

01/11/18 / #20180008700

Vaccination

The present invention relates to compositions for use in and methods for protecting against herpes zoster (hz).. . ... Glaxosmithkline Llc

01/11/18 / #20180008562

Oral dosage form containing a fast release exterior coating

Aspects of the present invention are directed to an oral dosage form comprising a core containing one more active ingredients and a fast-release exterior coating. The fast release exterior coating includes a water soluble polymer; a saccharide or sugar alcohol, or a combination thereof, and a flavoring. ... Glaxosmithkline Llc

01/04/18 / #20180002679

Compositions and methods for protein glycosylation

. . Described herein are oligosaccharyl transferases for use in n-glycosylating proteins of interest in vitro and in host cells. Methods for using such oligosaccharyl transferases, nucleic acids encoding such oligosaccharyl transferases, and host cells comprising such oligosaccharyl transferases are also provided herein. ... Glaxosmithkline Llc

01/04/18 / #20180000952

Enzyme and receptor modulation

Covalent conjugation of an alpha amino acid ester to a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid, leads to accumulation of the carboxylic acid hydrolysis product in the cell and enables improved or more prolonged enzyme or receptor modulation relative to the unconjugated modulator.. . ... Glaxosmithkline Llc

01/04/18 / #20180000805

Cyclopropylamines as lsd1 inhibitors

This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of lysine-specific demethylase 1 (lsd1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.. ... Glaxosmithkline Llc

12/28/17 / #20170369532

Cytomegalovirus antigens and uses thereof

. . This disclosure provides modified cytomegalovirus (cmv) gl proteins and complexes comprising gl proteins. The modified gl proteins remain intact and are able to form complexes with other cmv proteins.. ... Glaxosmithkline Llc

12/28/17 / #20170369448

Compounds for affinity chromatography and for extending the half-life of a therapeutic agent

Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (hsa) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to hsa, thereby providing a prolonged release of the therapeutic agent.. ... Glaxosmithkline Llc

12/21/17 / #20170362309

Nucleotide sequences, vectors and host cells

The present invention relates to fusion proteins comprising fragments from toxin a and/or toxin b of clostridium difficile, wherein the polypeptide elicits antibodies that neutralize toxin a or toxin b or both.. . ... Glaxosmithkline Llc

12/21/17 / #20170362278

Mammalian cells expressing cytomegalovirus antigens

This invention relates to cytomegalovirus (cmv) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular cho cells, in which the sequence(s) encoding cmv proteins gh, gl, pul128, pul130, pul131 (or a complex-forming fragment thereof) are stably integrated into the genome.. ... Glaxosmithkline Llc

12/21/17 / #20170362234

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. . ... Glaxosmithkline Llc

12/21/17 / #20170360915

Adjuvanting meningococcal factor h binding protein

Factor h binding protein (fhbp) has been proposed for use in immunising against serogroup b meningococcus (‘menb’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a ph which is equal to or below the adjuvant's point of zero charge (pzc), and/or (ii) selecting a fhbp and adjuvant with an isoelectric point/pzc within the range of 5.0 to 7, and/or (iii) selecting a fhbp with an isoelectric point above the adjuvant's pzc and using a buffer to bring the ph to within 1.2 ph units of the pzc. ... Glaxosmithkline Llc

12/14/17 / #20170355705

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. . ... Glaxosmithkline Llc

12/14/17 / #20170355697

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. ... Glaxosmithkline Llc

12/07/17 / #20170348408

Purification of streptococcal capsular polysaccharide

. . . . A purification method for the capsular polysaccharide of type ii gbs in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kda.. . ... Glaxosmithkline Llc

12/07/17 / #20170348407

Staphylococcus aureus proteins and nucleic acids

The invention provides proteins from staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.. ... Glaxosmithkline Llc

12/07/17 / #20170348329

Combination drug therapy

A novel combination comprising the 17 α-hydroxylase/c17,20 lyase inhibitor, (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a pi3kβ inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1h-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/c17,20 lyase and/or pi3kβ is beneficial, e.g., cancer.. . ... Glaxosmithkline Llc

12/07/17 / #20170348306

Methods of treating cancer

This invention relates to methods of treating cancer in a subject in need thereof, e.g., in a human in need thereof, comprising determining at least one of the following in a sample from said human: (a) the presence or absence of a mutation at the alanine 677 (a677) residue in ezh2 in a sample from said human; or (b) the presence or absence of a mutation at the tyrosine 641 (y641) residue in ezh2; or (c) the presence or absence of an increased level of h3k27me3 as compared to a control, and administering to said human an effective amount of an ezh2 inhibitor or a pharmaceutically acceptable salt thereof if at least one of said a677 mutation, y641 mutation, or increased level of h3k27me3 is present in said sample. . ... Glaxosmithkline Llc

11/30/17 / #20170342442

Recombinant self-replicating polycistronic rna molecules

This disclosure provides recombinant polycistronic nucleic acid molecules that contain at at least four nucleotide sequences that encode a protein of interest, particularly proteins that form complexes in vivo, each operably linked to a separate subgenomic promoter. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. ... Glaxosmithkline Llc

11/30/17 / #20170340720

Compositions for immunising against staphylococcus aureus

An effective staphylococcus aureus vaccine may require several antigenic components, and so various combinations of s. Aureus antigens are identified for use in immunisation. ... Glaxosmithkline Llc

11/30/17 / #20170340719

Immunogenic composition

The present invention relates to immunogenic compositions comprising a clostridium difficile (c. Difficile) polypeptide and an aluminium-free adjuvant.. ... Glaxosmithkline Llc

11/30/17 / #20170340617

Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. . ... Glaxosmithkline Llc

11/23/17 / #20170334891

Enhancer of zeste homolog 2 inhibitors

This invention relates to novel compounds according to formula (i) which are inhibitors of enhancer of zeste homolog 2 (ezh2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.. . ... Glaxosmithkline Llc

11/23/17 / #20170333550

Poxviral vaccines

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.. ... Glaxosmithkline Llc

11/23/17 / #20170333460

Long acting pharmaceutical compositions for hepatitis c

The present invention relates to pharmaceutical compositions useful in the treatment or prevention or cure of viral infections, such as hcv infections, and diseases associated with such infections.. . ... Glaxosmithkline Llc

11/09/17 / #20170320916

Complexes of cytomegalovirus proteins

An isolated human cytomegalovirus (hcmv) membrane protein complex that comprises gh, gl and at least one more hcmv glycoprotein is provided. In some embodiments the complex consists of gh, gl and go. ... Glaxosmithkline Llc

10/26/17 / #20170305928

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to important intermediates in the preparation of a compound which is an inhibitor of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1).. . ... Glaxosmithkline Llc

10/26/17 / #20170305888

Novel soluble guanylate cyclase activators and their use

The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.. ... Glaxosmithkline Llc

10/26/17 / #20170304301

Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

The present invention relates to methods for treating neisseria gonorrhoeae infection which comprises administering to a subject in need thereof novel tricyclic nitrogen containing compounds and corresponding pharmaceutical compositions as described herein.. . ... Glaxosmithkline Llc

10/26/17 / #20170304249

Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed

Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.. . ... Glaxosmithkline Llc

10/12/17 / #20170290905

Vaccine

. . . . . . . . The present invention relates to human rhinovirus (hrv) virus-like particles (vlps) and methods of making hrv vlps.. . ... Glaxosmithkline Llc

10/12/17 / #20170290902

Multiple variants of meningococcal protein nmb1870

Meningococcal protein nmb 1870 has been described in the prior art. The inventors have found that nmb 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. ... Glaxosmithkline Llc

10/12/17 / #20170290844

Methods of treatment

The present invention relates to methods of treating or preventing respiratory infections, in particular respiratory infections in patients with an underlying respiratory disorder such as chronic obstructive pulmonary disease (copd). The present invention also relates to methods of treating or preventing copd or copd exacerbations. ... Glaxosmithkline Llc

10/05/17 / #20170285024

Compliment factor i bioassay

The present invention relates to a cfi bioactivity assay designed to quantitatively measure (a) cfi bioactivity of plasma or other body fluids; and (b) bioactivity of cfi in plasma or other body fluids of a human patient afflicted by a disease that involves amyloid deposition in tissues, in particular alzheimer disease, amd, glaucoma, or beta-amyloid cataract formation.. . ... Glaxosmithkline Llc

10/05/17 / #20170283404

Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide

Disclosed are novel crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Llc

10/05/17 / #20170281744

Method of treatment

The application discloses a method of immunising against staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a staphylococcus aureus clfa protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the ph of the composition is ph 5.0-ph 8.0. The application further discloses an immunogenic composition comprising; (i) a s. ... Glaxosmithkline Llc

09/28/17 / #20170275371

Methods of treatment

Disclosed herein are combinations of an ox40 modulator and a tlr4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.. . ... Glaxosmithkline Llc

09/21/17 / #20170267665

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. . ... Glaxosmithkline Llc

09/21/17 / #20170266873

Package and heat sealing device

Aspects of the present invention are directed to a heat sealed packaging wherein the heat seal is along a curved surface. Additional aspects of the present invention are directed to a device for heat sealing a package on a surface that is curved along the direction of force.. ... Glaxosmithkline Llc

09/21/17 / #20170266199

Heterocyclic amides as rip1 kinase inhibitors as medicaments

Disclosed is a method of treating a rip1 kinase-mediated disease or disorder which comprises administering a therapeutically effective amount of a compound that inhibits rip1 kinase and at least one other therapeutically active agent to a patient in need thereof.. . ... Glaxosmithkline Llc

09/14/17 / #20170260266

Tslp binding proteins

. . The present disclosure relates to tslp binding proteins that interact with particular residues of human full length tslp, or contact particular regions of human full length tslp. The invention also includes pharmaceutical compositions and medical uses of these tslp binding proteins.. ... Glaxosmithkline Llc

09/14/17 / #20170260164

Cd38 inhibitors and methods of treatment

Compounds of formula i and methods of treating diseases of metabolism by modulating cellular nad+ levels through the inhibition of the cd38 enzyme, are disclosed.. . ... Glaxosmithkline Llc

09/07/17 / #20170252699

Ultrafiltration for preparing outer membrane vesicles

. . In place of a step of centrifugation during preparation of outer membrane vesicles (omvs) from bacteria, the invention utilises ultrafiltration. This allows much larger amounts of omv-containing supernatant to be processed in a much shorter time. ... Glaxosmithkline Llc

08/31/17 / #20170247421

Nucleotide sequences, vectors and host cells

Polynucleotides encoding fusion proteins comprising fragments of toxin a and toxin b from clostridium difficile are described, as well as vectors and host cells containing such polynucleotides.. . ... Glaxosmithkline Llc

08/31/17 / #20170246290

Oil-in-water emulsion influenza vaccine

The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 μg ha or a low amount such as less than 15 μg ha.. ... Glaxosmithkline Llc

08/31/17 / #20170246285

Conjugation of streptococcal capsular saccharides

Three conjugation methods for use with the capsular saccharide of streptococcus agalactiae. In the first method, reductive amination of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. ... Glaxosmithkline Llc

08/17/17 / #20170233156

Display pack

. . A display pack for consumer products, especially toothbrushes. A sheet form plastics material support has a lower edge with plural bubble packs for the product arranged lengthways along the edge, and detachably linked to the support part by a first separable link. ... Glaxosmithkline Llc

08/10/17 / #20170226161

Modified meningococcal fhbp polypeptides

The inventors have identified residues within variant 2 and variant 3 of meningococcal fhbp which can be modified to enhance their properties.. . ... Glaxosmithkline Llc

08/10/17 / #20170224803

Carrier molecule for antigens

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a bp-2a antigen and a spb1 antigen. Bp-2a and spb1 are streptococcus agalactiae antigens. ... Glaxosmithkline Llc

08/10/17 / #20170224685

Prmt5 inhibitors and uses thereof

Described herein are methods of treating cancer using one or more prmt5 inhibitors, for example using one or more compounds of formulae (1-5) or (a-f), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more prmt5 inhibitors, for example using one or more compounds of formulae (1-5) or (a-f), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.. ... Glaxosmithkline Llc

08/10/17 / #20170224679

Use of cxcr2 antagonists for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn)

The invention relates to the use of a cxcr2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn).. . ... Glaxosmithkline Llc

08/10/17 / #20170224616

Oil-in-water emulsions that contain nucleic acids

This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an rna molecule. The emulsion particles comprise an oil core and a cationic lipid. ... Glaxosmithkline Llc

08/03/17 / #20170218031

Clostridium difficile immunogenic composition

Immunogenic compositions comprising isolated clostridium difficile cdtb proteins, including modified proteins, and fusion proteins comprising a cdta protein and a cdtb protein.. . ... Glaxosmithkline Llc

07/27/17 / #20170209562

Immunogenic composition

The present disclosure relates to the field of neisserial immunogenic compositions and vaccines, their manufacture and the use of such compositions in medicine. In particular the present invention relates to compositions and methods involving the factor h binding protein (fhbp) antigen. ... Glaxosmithkline Llc

07/20/17 / #20170204131

Preparation and use of crystalline beta-d-nicotinamide riboside

Provided herein are crystalline beta-d-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. ... Glaxosmithkline Llc

07/20/17 / #20170204109

Compounds

The present invention relates to novel compounds that inhibit lp-pla2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of lp-pla2, for example alzheimer's disease.. . ... Glaxosmithkline Llc

07/20/17 / #20170204108

Compounds

The present invention relates to novel compounds that inhibit lp-pla2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of lp-pla2, for example atherosclerosis, alzheimer's disease.. . ... Glaxosmithkline Llc

07/20/17 / #20170202960

Cationic oil-in-water emulsions

This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. ... Glaxosmithkline Llc

07/13/17 / #20170197978

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ.. . ... Glaxosmithkline Llc

07/13/17 / #20170197972

Benzodiazepine bromodomain inhibitor

The present invention relates to a benzodiazepine compound, processes for its preparation, pharmaceutical compositions containing such a compound and to its use in therapy.. . ... Glaxosmithkline Llc

07/13/17 / #20170196968

Process for producing influenza vaccine

A process for producing a split influenza virus preparation or subunit influenza preparation comprising the steps of: (i) providing a whole virus preparation; (ii) splitting the whole virus preparation in the presence of a first detergent; (iii) adding t-octylphenoxypolyethoxyethanol (triton x-100™) to the resulting split virus preparation; and (iv) filtering the split virus preparation.. . ... Glaxosmithkline Llc

07/13/17 / #20170196961

Novel method for preventing or treating m tuberculosis infection

The present invention is directed to methods of preventing reactivation of active and latent m. Tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a mtb72f fusion protein, or a mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. ... Glaxosmithkline Llc

07/13/17 / #20170196960

Novel method and compositions

The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.. ... Glaxosmithkline Llc

07/06/17 / #20170190688

Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Disclosed are novel crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Glaxosmithkline Llc

07/06/17 / #20170189424

Fluticasone furoate in the treatment of copd

The present invention relates to pharmaceutical products comprising fluticasone furoate for use in the treatment of copd patients, particularly a subgroup of copd patients that through analysis have been identified as possessing an eosinophil blood count of≧150 cells/w. The present invention is further directed to methods for treating a patient with copd which methods include identifying a patient that will respond to treatment and administering a pharmaceutical product of the present invention comprising fluticasone furoate to said patient.. ... Glaxosmithkline Llc

07/06/17 / #20170189401

2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors

The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.. . ... Glaxosmithkline Llc

06/22/17 / #20170174767

Icos binding proteins

. . The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell. ... Glaxosmithkline Llc

06/22/17 / #20170174721

Buffer system for protein purification

A method for purifying a protein using a simplified, sodium chloride-free buffer system that consists of two components (acid and base pairs) for appropriate solution ph control; and a third component for ionic strength control, where the third component is the sodium salt conjugate base.. . ... Glaxosmithkline Llc

06/15/17 / #20170166894

Aptamers for topical delivery

Aptamers for topical delivery and methods for topical use of aptamers are described. Aptamers that bind to interleukin (il)-23 (il-23 aptamers) and methods of using such aptamers are also described.. ... Glaxosmithkline Llc

06/15/17 / #20170165346

Combination neisserial compositions

Compositions comprising a first biological molecule from a neisseria bacterium and a second biological molecule from a neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. ... Glaxosmithkline Llc

06/08/17 / #20170157113

4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

. . Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. . ... Glaxosmithkline Llc

05/18/17 / #20170137475

Expression system

. . Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or crm197 are provided herein.. . ... Glaxosmithkline Llc

05/18/17 / #20170136110

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.. . ... Glaxosmithkline Llc

05/11/17 / #20170128407

Novel formulations

. . The present invention is directed to a novel combination of excipients with an active ingredient, such as benzoyl peroxide based (bpo) which is subject to degradation. In one embodiment the invention is a topical pharmaceutical or cosmetic cleanser composition comprising benzoyl peroxide present in an amount from about 2.0 to about 20% w/w; water, at least one anionic surfactant which is a alkylpolyglucoside (ag) derivative surfactant; at least one humectant, a thickening agent, and optionally at least one dermatologically acceptable excipient.. ... Glaxosmithkline Llc

05/04/17 / #20170121313

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ.. . ... Glaxosmithkline Llc

05/04/17 / #20170119868

Adjuvanting meningococcal factor h binding protein

Factor h binding protein (fhbp) has been proposed for use in immunising against serogroup b meningococcus (‘menb’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a ph which is equal to or below the adjuvant's point of zero charge (pzc), and/or (ii) selecting a fhbp and adjuvant with an isoelectric point/pzc within the range of 5.0 to 7, and/or (iii) selecting a fhbp with an isoelectric point above the adjuvant's pzc and using a buffer to bring the ph to within 1.2 ph units of the pzc. ... Glaxosmithkline Llc

05/04/17 / #20170119864

Saccharide vaccine formulation

Substantially stable vaccine compositions are provided, as are methods for their use and manufacture.. . ... Glaxosmithkline Llc

04/27/17 / #20170112914

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an m72 related antigen and wherein a subsequent administration is delayed.. . ... Glaxosmithkline Llc

04/27/17 / #20170112844

Benzimidazole derivatives as pi3 kinase inhibitors

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. ... Glaxosmithkline Llc

04/20/17 / #20170106070

Uses of parasite macrophage migration inhibitory factors

This invention relates to compositions (e.g. Vaccine compositions) which can be used to provide a subject with protective immunity against a parasite infection. ... Glaxosmithkline Llc

04/20/17 / #20170105997

Methods of treating cancer

Disclosed are methods for treating cancer such as a myeloid malignancy such as multiple myeloma in a human using ezh2 inhibitors in human populations having a translocation mmset or a decreased level of a functional utx protein or both.. . ... Glaxosmithkline Llc

04/13/17 / #20170101399

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ. . ... Glaxosmithkline Llc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxosmithkline Llc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Llc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###